NCT05755061

Brief Summary

This study is a randomized controlled trial (RCT) that compares the effects of two different 12-month aerobic walking exercise programs on cognitive processing speed (CPS), brain MRI, and other functional outcomes in 32 adults with multiple sclerosis (MS) who are able to walk without an assistive device but demonstrate slowed CPS. Participants (N=32) will initially undergo screening via telephone, and after satisfying relevant inclusion/exclusion criteria, will provide informed consent, followed by a baseline assessment of CPS remotely via a HIPAA-compliant virtual platform (i.e., Zoom for Healthcare). This assessment will also serve as a screen for ensuring impaired CPS. Following this virtual session, participants will come into Kessler Foundation (KF) and complete a 3-hour baseline assessment (T0) that includes a relatively short battery of neuropsychological tests, a 40-minute MRI scan, tests of walking function, a short questionnaire packet, followed by cardiopulmonary exercise testing on a motor-driven treadmill. Following T0, participants will be randomly assigned into one of the two aerobic walking ET programs that are remotely-delivered and supported by KF research assistants. As the conditions are delivered and supported remotely by KF personnel, the exercise itself takes place in the home/community setting. Both conditions involve behavior coaching via Zoom for Healthcare. The experimental condition involves high-frequency, high-intensity aerobic walking ET that exceeds the published guidelines for physical activity for adults with MS (GEMS+). GEMS + initially involves 10 minutes of moderate intensity aerobic walking exercise for 3 days per week and progresses to upwards of 40 minutes of vigorous intensity aerobic walking exercise for 5 days per week by month 12. The comparison condition involves mild-to-moderate aerobic walking exercise training that approximates published guidelines (GEMS). GEMS initially involves 10 minutes of light intensity aerobic walking exercise for 2 days per week and progresses up to 30 minutes of moderate intensity aerobic walking exercise for 3 days per week. Both conditions further will be monitored based on Fitbit-measured steps per exercise session. Of note, the sample size will be enrolled using 2 overlapping waves (Wave 1 = 14 participants, Wave 2 = 18 participants), 3 months apart. Participants will return to KF at the mid-point (i.e., T6) and end-point (i.e., T12) of the 12-month intervention period to complete the same assessments as T0. The T6 and T12 outcomes will be administered by treatment-blinded research assistants.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
31

participants targeted

Target at P50-P75 for phase_1 multiple-sclerosis

Timeline
Completed

Started Feb 2023

Typical duration for phase_1 multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2023

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

February 23, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 6, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2025

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2026

Completed
Last Updated

August 28, 2025

Status Verified

August 1, 2025

Enrollment Period

2.1 years

First QC Date

February 23, 2023

Last Update Submit

August 27, 2025

Conditions

Keywords

ExerciseCognitionBrainRehabilitationRemote

Outcome Measures

Primary Outcomes (2)

  • Change in cognitive processing speed

    Participants will undertake the Symbol Digit Modalities Test as a cognitive test of cognitive processing speed as one of the primary study outcomes

    Baseline; 6-months; 12-months

  • Change in resting-state functional connectivity

    Participants will undertake an fMRI scan to measure resting-state functional connectivity between the thalamus and other brain regions as one of the primary study outcomes

    Baseline; 6-months; 12-months

Secondary Outcomes (1)

  • Change in thalamic volume

    Baseline; 6-months; 12-months

Other Outcomes (1)

  • Change in aerobic fitness

    Baseline; 6-months; 12-months

Study Arms (2)

GEMS Plus

EXPERIMENTAL

Home-based aerobic walking exercise that exceeds published physical activity guidelines for adults with MS

Behavioral: GEMS Plus

GEMS

ACTIVE COMPARATOR

Home-based aerobic walking exercise that meets published physical activity guidelines for adults with MS

Behavioral: GEMS

Interventions

GEMS PlusBEHAVIORAL

12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS

GEMS Plus
GEMSBEHAVIORAL

12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS

GEMS

Eligibility Criteria

Age16 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Definite MS diagnosis
  • Relapse-free for at least 30 days
  • Have Internet access on a device larger than a smartphone
  • Willingness and ability to travel to Kessler Foundation 3 times over a 12-month period
  • Be insufficiently physically active
  • Demonstrate low fall risk based on Activities Specific Balance Confidence scores
  • Demonstrate low contraindications for exercise
  • Right handedness
  • English as a primary language
  • Demonstrate low cognitive processing speed based on a Zoom-administered Symbol Digit Modalities Test

You may not qualify if:

  • Acutely taken corticosteroids within 30 days of enrollment
  • Use an assistive device (i.e., cane, crutch, walker, rollator) for ambulation
  • Experienced a fall in the past 6 months
  • Have uncontrolled major depressive disorder or history of bipolar disorder or schizophrenia
  • Regularly taking medications that can affect cognition (e.g., antipsychotics, benzodiazepines)
  • Demonstrate contraindications for 3T MRI (i.e., having metal/shrapnel in the body, non-MRI compatible aneurysm clips)
  • Have severe cognitive impairment causing an inability to follow directions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kessler Foundation

West Orange, New Jersey, 07052, United States

Location

MeSH Terms

Conditions

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMotor Activity

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesBehavior

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Research Scientist

Study Record Dates

First Submitted

February 23, 2023

First Posted

March 6, 2023

Study Start

February 1, 2023

Primary Completion

February 28, 2025

Study Completion

January 31, 2026

Last Updated

August 28, 2025

Record last verified: 2025-08

Locations